197 related articles for article (PubMed ID: 20579375)
1. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis.
Ralhan R; Cao J; Lim T; Macmillan C; Freeman JL; Walfish PG
BMC Cancer; 2010 Jun; 10():331. PubMed ID: 20579375
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.
Kunavisarut T; Kak I; Macmillan C; Ralhan R; Walfish PG
BMC Cancer; 2012 Nov; 12():523. PubMed ID: 23153310
[TBL] [Abstract][Full Text] [Related]
3. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
4. Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.
Ralhan R; He HC; So AK; Tripathi SC; Kumar M; Hasan MR; Kaur J; Kashat L; MacMillan C; Chauhan SS; Freeman JL; Walfish PG
PLoS One; 2010 Nov; 5(11):e14130. PubMed ID: 21152431
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.
Srivastava G; Assi J; Kashat L; Matta A; Chang M; Walfish PG; Ralhan R
BMC Cancer; 2014 Sep; 14():726. PubMed ID: 25265904
[TBL] [Abstract][Full Text] [Related]
6. Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.
Assi J; Srivastava G; Matta A; MacMillan C; Ralhan R; Walfish PG
PLoS One; 2015; 10(2):e0107586. PubMed ID: 25695234
[TBL] [Abstract][Full Text] [Related]
7. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.
Fong D; Moser P; Kasal A; Seeber A; Gastl G; Martowicz A; Wurm M; Mian C; Obrist P; Mazzoleni G; Spizzo G
Histopathology; 2014 Apr; 64(5):683-92. PubMed ID: 24117877
[TBL] [Abstract][Full Text] [Related]
8. Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis.
Somasundaram RT; Kaur J; Leong I; MacMillan C; Witterick IJ; Walfish PG; Ralhan R
BMC Cancer; 2016 Jul; 16():486. PubMed ID: 27421772
[TBL] [Abstract][Full Text] [Related]
9. Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis.
Warneke VS; Behrens HM; Haag J; Krüger S; Simon E; Mathiak M; Ebert MP; Röcken C
Br J Cancer; 2013 Oct; 109(8):2217-27. PubMed ID: 24008668
[TBL] [Abstract][Full Text] [Related]
10. Loss of membranous Ep-CAM in budding colorectal carcinoma cells.
Gosens MJ; van Kempen LC; van de Velde CJ; van Krieken JH; Nagtegaal ID
Mod Pathol; 2007 Feb; 20(2):221-32. PubMed ID: 17361206
[TBL] [Abstract][Full Text] [Related]
11. beta-Catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas.
Rezk S; Brynes RK; Nelson V; Thein M; Patwardhan N; Fischer A; Khan A
Endocr Pathol; 2004; 15(4):329-37. PubMed ID: 15681857
[TBL] [Abstract][Full Text] [Related]
12. The role of nuclear EpICD in extrahepatic cholangiocarcinoma: association with β-catenin.
Jachin S; Bae JS; Sung JJ; Park HS; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Aug; 45(2):691-8. PubMed ID: 24888903
[TBL] [Abstract][Full Text] [Related]
13. [Expression of EpCAM and E-cadherin in papillary thyroid carcinoma and its clinicopathologic significance].
Cheng Y; Meng Y; Liang Z; Yang C; Luo Y; Cui Q
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):189-94. PubMed ID: 26268754
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic Trop-1/Ep-CAM overexpression is associated with a favorable outcome in node-positive breast cancer.
Alberti S; Ambrogi F; Boracchi P; Fornili M; Querzoli P; Pedriali M; La Sorda R; Lattanzio R; Tripaldi R; Piantelli M; Biganzoli E; Coradini D
Jpn J Clin Oncol; 2012 Dec; 42(12):1128-37. PubMed ID: 23072840
[TBL] [Abstract][Full Text] [Related]
15. Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas.
Fong D; Seeber A; Terracciano L; Kasal A; Mazzoleni G; Lehne F; Gastl G; Spizzo G
J Clin Pathol; 2014 May; 67(5):408-14. PubMed ID: 24465008
[TBL] [Abstract][Full Text] [Related]
16. Epithelial Cell Adhesion Molecule in Primary Sjögren's Syndrome Patients: Characterization and Evaluation of a Potential Biomarker.
Zhang K; Zhou Y; Cheng X; Fu X; Du W; Feng Y; Jia J; Yang X; Xiao G; Zheng Z; Zhu P; Wu Z
J Immunol Res; 2019; 2019():3269475. PubMed ID: 31886299
[TBL] [Abstract][Full Text] [Related]
17. Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells.
Liang KH; Tso HC; Hung SH; Kuan II; Lai JK; Ke FY; Chuang YT; Liu IJ; Wang YP; Chen RH; Wu HC
Cancer Lett; 2018 Oct; 433():165-175. PubMed ID: 29981429
[TBL] [Abstract][Full Text] [Related]
18. The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung.
Piyathilake CJ; Frost AR; Weiss H; Manne U; Heimburger DC; Grizzle WE
Hum Pathol; 2000 Apr; 31(4):482-7. PubMed ID: 10821496
[TBL] [Abstract][Full Text] [Related]
19. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance.
Fong D; Steurer M; Obrist P; Barbieri V; Margreiter R; Amberger A; Laimer K; Gastl G; Tzankov A; Spizzo G
J Clin Pathol; 2008 Jan; 61(1):31-5. PubMed ID: 16775119
[TBL] [Abstract][Full Text] [Related]
20. Nuclear signalling by tumour-associated antigen EpCAM.
Maetzel D; Denzel S; Mack B; Canis M; Went P; Benk M; Kieu C; Papior P; Baeuerle PA; Munz M; Gires O
Nat Cell Biol; 2009 Feb; 11(2):162-71. PubMed ID: 19136966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
